Recently, it has become increasingly clear that CD4+ T cells play a critical role in developing and sustaining effective anti-tumour immunity, even in cancer immunotherapies specifically designed to activate a CD8+ CTL response. The gene discussed is CD8A; the disease is neoplasm.